Cargando…

Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06

PURPOSE: The O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at...

Descripción completa

Detalles Bibliográficos
Autores principales: Barry, Nathaniel, Francis, Roslyn J., Ebert, Martin A., Koh, Eng-Siew, Rowshanfarzad, Pejman, Hassan, Ghulam Mubashar, Kendrick, Jake, Gan, Hui K., Lee, Sze T., Lau, Eddie, Moffat, Bradford A., Fitt, Greg, Moore, Alisha, Thomas, Paul, Pattison, David A., Akhurst, Tim, Alipour, Ramin, Thomas, Elizabeth L., Hsiao, Edward, Schembri, Geoffrey P., Lin, Peter, Ly, Tam, Yap, June, Kirkwood, Ian, Vallat, Wilson, Khan, Shahroz, Krishna, Dayanethee, Ngai, Stanley, Yu, Chris, Beuzeville, Scott, Yeow, Tow C., Bailey, Dale, Cook, Olivia, Whitehead, Angela, Dykyj, Rachael, Rossi, Alana, Grose, Andrew, Scott, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611835/
https://www.ncbi.nlm.nih.gov/pubmed/37563351
http://dx.doi.org/10.1007/s00259-023-06371-5
_version_ 1785128571905245184
author Barry, Nathaniel
Francis, Roslyn J.
Ebert, Martin A.
Koh, Eng-Siew
Rowshanfarzad, Pejman
Hassan, Ghulam Mubashar
Kendrick, Jake
Gan, Hui K.
Lee, Sze T.
Lau, Eddie
Moffat, Bradford A.
Fitt, Greg
Moore, Alisha
Thomas, Paul
Pattison, David A.
Akhurst, Tim
Alipour, Ramin
Thomas, Elizabeth L.
Hsiao, Edward
Schembri, Geoffrey P.
Lin, Peter
Ly, Tam
Yap, June
Kirkwood, Ian
Vallat, Wilson
Khan, Shahroz
Krishna, Dayanethee
Ngai, Stanley
Yu, Chris
Beuzeville, Scott
Yeow, Tow C.
Bailey, Dale
Cook, Olivia
Whitehead, Angela
Dykyj, Rachael
Rossi, Alana
Grose, Andrew
Scott, Andrew M.
author_facet Barry, Nathaniel
Francis, Roslyn J.
Ebert, Martin A.
Koh, Eng-Siew
Rowshanfarzad, Pejman
Hassan, Ghulam Mubashar
Kendrick, Jake
Gan, Hui K.
Lee, Sze T.
Lau, Eddie
Moffat, Bradford A.
Fitt, Greg
Moore, Alisha
Thomas, Paul
Pattison, David A.
Akhurst, Tim
Alipour, Ramin
Thomas, Elizabeth L.
Hsiao, Edward
Schembri, Geoffrey P.
Lin, Peter
Ly, Tam
Yap, June
Kirkwood, Ian
Vallat, Wilson
Khan, Shahroz
Krishna, Dayanethee
Ngai, Stanley
Yu, Chris
Beuzeville, Scott
Yeow, Tow C.
Bailey, Dale
Cook, Olivia
Whitehead, Angela
Dykyj, Rachael
Rossi, Alana
Grose, Andrew
Scott, Andrew M.
author_sort Barry, Nathaniel
collection PubMed
description PURPOSE: The O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation. METHODS: Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBR(max)), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR (TBR(max)/TBR(mean)) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]). RESULTS: Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBR(max), and TBR(mean) were 21.53% (12.00–30.10%), 5.89% (5.01–6.68%), and 5.01% (3.37–6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63–0.97) with good spatial (DSC = 0.84 ± 0.09) and boundary (HD = 15.78 ± 8.30 mm; MASD = 1.47 ± 1.36 mm) agreement. CONCLUSION: The FIG study credentialing program has increased expertise across study sites. TBR(max) and TBR(mean) were robust, with considerable variability in BTV delineation and image interpretation observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06371-5.
format Online
Article
Text
id pubmed-10611835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106118352023-10-29 Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06 Barry, Nathaniel Francis, Roslyn J. Ebert, Martin A. Koh, Eng-Siew Rowshanfarzad, Pejman Hassan, Ghulam Mubashar Kendrick, Jake Gan, Hui K. Lee, Sze T. Lau, Eddie Moffat, Bradford A. Fitt, Greg Moore, Alisha Thomas, Paul Pattison, David A. Akhurst, Tim Alipour, Ramin Thomas, Elizabeth L. Hsiao, Edward Schembri, Geoffrey P. Lin, Peter Ly, Tam Yap, June Kirkwood, Ian Vallat, Wilson Khan, Shahroz Krishna, Dayanethee Ngai, Stanley Yu, Chris Beuzeville, Scott Yeow, Tow C. Bailey, Dale Cook, Olivia Whitehead, Angela Dykyj, Rachael Rossi, Alana Grose, Andrew Scott, Andrew M. Eur J Nucl Med Mol Imaging Original Article PURPOSE: The O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation. METHODS: Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBR(max)), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR (TBR(max)/TBR(mean)) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]). RESULTS: Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBR(max), and TBR(mean) were 21.53% (12.00–30.10%), 5.89% (5.01–6.68%), and 5.01% (3.37–6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63–0.97) with good spatial (DSC = 0.84 ± 0.09) and boundary (HD = 15.78 ± 8.30 mm; MASD = 1.47 ± 1.36 mm) agreement. CONCLUSION: The FIG study credentialing program has increased expertise across study sites. TBR(max) and TBR(mean) were robust, with considerable variability in BTV delineation and image interpretation observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06371-5. Springer Berlin Heidelberg 2023-08-11 2023 /pmc/articles/PMC10611835/ /pubmed/37563351 http://dx.doi.org/10.1007/s00259-023-06371-5 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Barry, Nathaniel
Francis, Roslyn J.
Ebert, Martin A.
Koh, Eng-Siew
Rowshanfarzad, Pejman
Hassan, Ghulam Mubashar
Kendrick, Jake
Gan, Hui K.
Lee, Sze T.
Lau, Eddie
Moffat, Bradford A.
Fitt, Greg
Moore, Alisha
Thomas, Paul
Pattison, David A.
Akhurst, Tim
Alipour, Ramin
Thomas, Elizabeth L.
Hsiao, Edward
Schembri, Geoffrey P.
Lin, Peter
Ly, Tam
Yap, June
Kirkwood, Ian
Vallat, Wilson
Khan, Shahroz
Krishna, Dayanethee
Ngai, Stanley
Yu, Chris
Beuzeville, Scott
Yeow, Tow C.
Bailey, Dale
Cook, Olivia
Whitehead, Angela
Dykyj, Rachael
Rossi, Alana
Grose, Andrew
Scott, Andrew M.
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06
title Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06
title_full Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06
title_fullStr Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06
title_full_unstemmed Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06
title_short Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06
title_sort delineation and agreement of fet pet biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating fet pet in glioblastoma (fig) study—trog 18.06
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611835/
https://www.ncbi.nlm.nih.gov/pubmed/37563351
http://dx.doi.org/10.1007/s00259-023-06371-5
work_keys_str_mv AT barrynathaniel delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT francisroslynj delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT ebertmartina delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT kohengsiew delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT rowshanfarzadpejman delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT hassanghulammubashar delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT kendrickjake delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT ganhuik delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT leeszet delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT laueddie delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT moffatbradforda delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT fittgreg delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT moorealisha delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT thomaspaul delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT pattisondavida delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT akhursttim delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT alipourramin delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT thomaselizabethl delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT hsiaoedward delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT schembrigeoffreyp delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT linpeter delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT lytam delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT yapjune delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT kirkwoodian delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT vallatwilson delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT khanshahroz delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT krishnadayanethee delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT ngaistanley delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT yuchris delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT beuzevillescott delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT yeowtowc delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT baileydale delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT cookolivia delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT whiteheadangela delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT dykyjrachael delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT rossialana delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT groseandrew delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806
AT scottandrewm delineationandagreementoffetpetbiologicalvolumesinglioblastomaresultsofthenuclearmedicinecredentialingprogramfromtheprospectivemulticentretrialevaluatingfetpetinglioblastomafigstudytrog1806